Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Myrobalan Therapeutics

Request full access

Harnessing common disease mechanisms to create breakthrough small molecule therapeutics

Medford, United StatesFounded 2021Biotech & Life Sciences

About Myrobalan Therapeutics

Myrobalan Therapeutics is a biotechnology firm established in 2021, focusing on the development of oral neurorestorative therapies aimed at reversing key pathological processes in central nervous system (CNS) disorders. The company was co-founded by an experienced team including Dr. Alex Nivorozhkin, who serves as the President and Chief Executive Officer, Dr. Steven Gullans, the Chief Scientific Officer, and Dr. Jin-A Lee, the Director of R&D. The founders bring a wealth of experience in drug discovery and development, particularly in the CNS space, having previously worked together at pioneering companies like Gensaic, which also focused on CNS therapeutics. Dr. Nivorozhkin has a notable track record in identifying and advancing novel therapeutic candidates from inception to clinical trials.

The company's core mission is to address significant unmet needs in neurodegenerative, demyelinating, and neuropsychiatric disorders by promoting remyelination, the process of rebuilding the protective myelin sheath around nerves. Its primary therapeutic candidate, MRO-103, is an orally administered small molecule designed to stimulate the generation of new oligodendrocytes, the cells responsible for myelination in the brain. This approach holds potential for treating conditions like multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS) by not just slowing disease progression but potentially restoring neurological function. Myrobalan operates on a research and development-centric business model, likely generating future revenue through partnerships, licensing agreements with larger pharmaceutical companies, or the eventual commercialization of its therapeutic candidates following successful clinical trials and regulatory approval.

In a significant milestone, Myrobalan Therapeutics secured a $24 million Series A financing round in 2021, co-led by founding investor OrbiMed and Samsara BioCapital. This funding is being utilized to advance its pipeline of remyelinating therapies, with the goal of bringing its lead candidate, MRO-103, into clinical development. The company's strategy involves a deep understanding of the underlying biology of CNS disorders to develop targeted and effective treatments that can offer substantial improvements over existing therapies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
15
Open positions
None listed
Dealroom signal
68.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jul 2024 $9M $120M Undisclosed ↗
GRANT✓Other financing Feb 2024 $400K — The ALS Association ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Myrobalan Therapeutics website traffic

Latest recorded traffic for Myrobalan Therapeutics is 6.1K monthly website visits, up 306.7% over the last three months. Myrobalan Therapeutics's team grew 0% over the past year.

Latest monthly visits6.1K 3-month web change+306.7% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Mirexus Biotechnologies, Inc.Corn-based phytoglycogen nanoparticles for cosmetic and personal care Kitchener, Canada Operational 9 $18M —
Aperiam BioTaking the guesswork out of biotechnology with computer vision that illuminates critical parts of protein chemistry New York City, United States Operational
LucencePrecision oncology company dedicated to creating state-of-the-art, highly sensitive liquid biopsy tests for early disease detection and personalized treatment selection Palo Alto, United States Operational
Dyno TherapeuticsUtilizing next-gen DNA technologies and machine learning to engineer AAV capsids for effective delivery of gene therapies Watertown, United States Operational
Iota BiosciencesDeveloping a platform to empower the future of bioelectronic medicine Berkeley, United States Acquired
GenEditDeveloping innovative therapies through targeted delivery of genetic medicines Brisbane, United States Operational
CrystalplexA biochemistry and diagnostics laboratory, specializing in nanotechnology for the life sciences industry Pittsburgh, United States Operational
Xalud TherapeuticsDiscovers, develops, and provides novel treatments for chronic inflammatory diseases that can dramatically improve the health and quality of life for millions of suffering patients New York City, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Myrobalan Therapeutics in the Medford ecosystem

Live from Dealroom

The Myrobalan Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • The ALS Association

Series A4 investors entered at this stage

  • 3E Bioventures
  • AB Magnitude Ventures
  • Guan Zi Equity Investment
  • Cowin Venture

Other known investors1 additional known investor

  • Harvard University
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Myrobalan Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Myrobalan Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.